These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24725236)

  • 21. Cure with ledipasvir/sofosbuvir for chronic hepatitis C virus in an individual with gastric bypass.
    Johnson SW; Teachey AL; Valanejad SM; Griffin SM; Weber SF
    J Clin Pharm Ther; 2017 Oct; 42(5):624-626. PubMed ID: 28474386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hope for Cirrhosis Patients with Genotype 1 Hepatitis C Virus Who Failed the Previous Treatment].
    Kwon JH
    Korean J Gastroenterol; 2015 Aug; 66(2):131-3. PubMed ID: 26513826
    [No Abstract]   [Full Text] [Related]  

  • 23. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
    Afdhal N; Zeuzem S; Kwo P; Chojkier M; Gitlin N; Puoti M; Romero-Gomez M; Zarski JP; Agarwal K; Buggisch P; Foster GR; Bräu N; Buti M; Jacobson IM; Subramanian GM; Ding X; Mo H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Mangia A; Marcellin P;
    N Engl J Med; 2014 May; 370(20):1889-98. PubMed ID: 24725239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
    Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment.
    Gentile I; Borgia G
    Evid Based Med; 2014 Dec; 19(6):223-4. PubMed ID: 25028605
    [No Abstract]   [Full Text] [Related]  

  • 26. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
    Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generic Ledipasvir-Sofosbuvir Treatment for Adolescents With Chronic Hepatitis C Virus Infection.
    Fouad HM; Sabry MA; Ahmed A; Hassany M; Al Soda MF; Abdel Aziz H
    J Pediatric Infect Dis Soc; 2020 Jul; 9(3):386-389. PubMed ID: 31310312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
    Kowdley KV; Gordon SC; Reddy KR; Rossaro L; Bernstein DE; Lawitz E; Shiffman ML; Schiff E; Ghalib R; Ryan M; Rustgi V; Chojkier M; Herring R; Di Bisceglie AM; Pockros PJ; Subramanian GM; An D; Svarovskaia E; Hyland RH; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Pound D; Fried MW;
    N Engl J Med; 2014 May; 370(20):1879-88. PubMed ID: 24720702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hepatitis C genotype 1. Harvoni and Holkira Pak reimbursed?].
    Sabourin G
    Perspect Infirm; 2015; 12(5):60. PubMed ID: 26730433
    [No Abstract]   [Full Text] [Related]  

  • 31. Resolution of porphyria cutanea tarda in HIV and mixed HCV coinfection after direct-acting antiviral (DAA) therapy.
    Bruzzone B; Magnani O; Sticchi L; Canepa P; Rappazzo E; Icardi G; Setti M
    J Antimicrob Chemother; 2017 Oct; 72(10):2955-2958. PubMed ID: 29091216
    [No Abstract]   [Full Text] [Related]  

  • 32. Evidence of HCV recovery after therapy of hepatitis C virus infection by direct acting antivirals.
    Parlati L; Sirmai L; Dupuy CA; Glotz D; Pol S
    Clin Res Hepatol Gastroenterol; 2019 Apr; 43(2):e18-e19. PubMed ID: 30293896
    [No Abstract]   [Full Text] [Related]  

  • 33. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
    Naggie S; Cooper C; Saag M; Workowski K; Ruane P; Towner WJ; Marks K; Luetkemeyer A; Baden RP; Sax PE; Gane E; Santana-Bagur J; Stamm LM; Yang JC; German P; Dvory-Sobol H; Ni L; Pang PS; McHutchison JG; Stedman CA; Morales-Ramirez JO; Bräu N; Jayaweera D; Colson AE; Tebas P; Wong DK; Dieterich D; Sulkowski M;
    N Engl J Med; 2015 Aug; 373(8):705-13. PubMed ID: 26196665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Sofosbuvir/ledipasvir is also effective in routine general practice].
    Warpakowski A
    MMW Fortschr Med; 2016 Apr; 158 Spec No 1():65. PubMed ID: 27090681
    [No Abstract]   [Full Text] [Related]  

  • 35. Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients.
    Huysentruyt K; Stephenne X; Varma S; Scheers I; Leclercq G; Smets F; Sokal EM
    Liver Transpl; 2017 Apr; 23(4):552-553. PubMed ID: 28006874
    [No Abstract]   [Full Text] [Related]  

  • 36. Hepatitis C Virus and Schizophrenia: Expanding the Role of the Community Psychiatrist.
    Herold S; Freudenreich O
    Psychosomatics; 2016; 57(6):634-637. PubMed ID: 27418108
    [No Abstract]   [Full Text] [Related]  

  • 37. New Indications for Harvoni.
    Med Lett Drugs Ther; 2016 Jan; 58(1485):6. PubMed ID: 27099890
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
    Buti M; Domínguez-Hernández R; Oyagüez I; Casado MA; Esteban R
    J Viral Hepat; 2017 Sep; 24(9):750-758. PubMed ID: 28273410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
    Younossi ZM; Park H; Saab S; Ahmed A; Dieterich D; Gordon SC
    Aliment Pharmacol Ther; 2015 Mar; 41(6):544-63. PubMed ID: 25619871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.
    Tapper EB; Bacon BR; Curry MP; Dieterich DT; Flamm SL; Guest LE; Kowdley KV; Lee Y; Tsai NC; Younossi ZM; Afdhal NH
    J Viral Hepat; 2017 Jan; 24(1):22-27. PubMed ID: 27730717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.